



July 3, 2017, 11:45 p.m.

Ad hoc Release

STADA Arzneimittel AG confirms that Bain Capital and Cinven are considering to apply for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover offer

Bad Vilbel, July 3, 2017 – STADA Arzneimittel AG confirms that Nidda Healthcare Holding AG, the acquiring company of Bain Capital and Cinven, gave notice to be considering to submit an application to the German Federal Financial Supervisory Authority (BaFin) for an exemption from the one-year exclusion period to make a renewed voluntary public takeover offer under section 26(2) of the German Securities Acquisition and Takeover Act (WpÜG). STADA is currently assessing whether the company would give its consent to the exemption from the exclusion period and will keep both the capital market and the public updated on further progress in this regard, in line with the applicable legal requirements.

Contact:

STADA Arzneimittel AG / Investor Relations / Leslie Iltgen / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /

Tel.: +49 (0) 6101 603-173 / Fax: +49 (0) 6101 603-215 / E-mail: leslie.iltgen@stada.de

Or visit us on the internet at www.stada.com

Executive Board: Dr. Matthias Wiedenfels (Chairman) / Helmut Kraft / Dr. Barthold Piening
Chairman of the Supervisory Board: Carl Ferdinand Oetker